Cost-utility analysis of opportunistic and systematic diabetic retinopathy screening strategies from the perspective of the Brazilian Public Healthcare System
dc.contributor.author | Ben, Ângela Jornada | pt_BR |
dc.contributor.author | Neyeloff, Jeruza Lavanholi | pt_BR |
dc.contributor.author | Souza, Camila Furtado de | pt_BR |
dc.contributor.author | Rosses, Ana Paula Oliveira | pt_BR |
dc.contributor.author | Araújo, Aline Lutz de | pt_BR |
dc.contributor.author | Szortika, Adriana Dietrich | pt_BR |
dc.contributor.author | Locatelli, Franciele Daiane | pt_BR |
dc.contributor.author | Carvalho, Gabriela de | pt_BR |
dc.contributor.author | Neumann, Cristina Rolim | pt_BR |
dc.date.accessioned | 2020-03-14T04:19:27Z | pt_BR |
dc.date.issued | 2020 | pt_BR |
dc.identifier.issn | 1179-1896 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/206809 | pt_BR |
dc.description.abstract | Objective: To perform a cost-utility analysis of diabetic retinopathy (DR) screening strategies from the perspective of the Brazilian Public Healthcare System. Methods: A model-based economic evaluation was performed to estimate the incremental costs per quality-adjusted life-year (QALY) gained between three DR screening strategies: (1) the opportunistic ophthalmology referral-based (usual practice), (2) the systematic ophthalmology referral-based, and (3) the systematic teleophthalmology-based. The target population included individuals with type 2 diabetes (T2D) aged 40 years, without retinopathy, followed over a 40-year time horizon. A Markov model was developed with five health states and a 1-year cycle. Model parameters were based on literature and country databases. One-way and probabilistic sensitivity analyses were performed to assess model parameters’ uncertainty. WHO willingness-to-pay (WHO-WTP) thresholds were used as reference (i.e. one and three times the Brazilian per capita Gross Domestic Product of R$32747 in 2018). Results: Compared to usual practice, the systematic teleophthalmology-based screening was associated with an incremental cost of R$21445/QALY gained ($9792/QALY gained). The systematic ophthalmology referral-based screening was more expensive (incremental costs = R$4) and less effective (incremental QALY = −0.012) compared to the systematic teleophthalmology-based screening. The probability of systematic teleophthalmology-based screening being cost-effective compared to usual practice was 0.46 and 0.67 at the minimum and the maximum WHO-WTP thresholds, respectively. Conclusion: Systematic teleophthalmology-based DR screening for the Brazilian population with T2D would be considered very cost effective compared to the opportunistic ophthalmology referral-based screening according to the WHO-WTP threshold. However, there is still a considerable amount of uncertainty around the results. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Applied health economics and health policy. Auckland. vol. 18 (2020), p. 57-68 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Sistema Único de Saúde | pt_BR |
dc.subject | Retinopatia diabética | pt_BR |
dc.subject | Análise custo-benefício | pt_BR |
dc.title | Cost-utility analysis of opportunistic and systematic diabetic retinopathy screening strategies from the perspective of the Brazilian Public Healthcare System | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001113402 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (40977)Ciências da Saúde (10957)